These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18552239)

  • 1. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study).
    Kim SG; Kim S; Hwang YH; Kim K; Oh JE; Chung W; Oh KH; Kim HJ; Ahn C;
    Perit Dial Int; 2008 Jun; 28 Suppl 3():S117-22. PubMed ID: 18552239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.
    Kim S; Oh J; Kim S; Chung W; Ahn C; Kim SG; Oh KH
    Nephrol Dial Transplant; 2009 Sep; 24(9):2899-908. PubMed ID: 19258384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
    Lui SL; Yung S; Yim A; Wong KM; Tong KL; Wong KS; Li CS; Au TC; Lo WK; Ho YW; Ng F; Tang C; Chan TM
    Am J Kidney Dis; 2012 Dec; 60(6):966-75. PubMed ID: 22835900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The
    Htay H; Cho Y; Pascoe EM; Darssan D; Hawley C; Johnson DW;
    Perit Dial Int; 2017; 37(3):283-289. PubMed ID: 27935537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Trio Trial - A Randomized Controlled Clinical Trial Evaluating the Effect of a Biocompatible Peritoneal Dialysis Solution on Residual Renal Function.
    Sikaneta T; Wu G; Abdolell M; Ng A; Mahdavi S; Svendrovski A; Tu T; Mercer T; Tong M; Oreopoulos D; Tam P
    Perit Dial Int; 2016 9-10; 36(5):526-32. PubMed ID: 27282852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
    Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
    Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
    Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
    Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
    Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
    Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.
    Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi M; Tan SH; Voss D;
    J Am Soc Nephrol; 2012 Jun; 23(6):1097-107. PubMed ID: 22440906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis.
    Wang J; Zhu N; Yuan W
    Nephron; 2015; 129(3):155-63. PubMed ID: 25765060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
    Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
    BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
    Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
    Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ Trial.
    Cho Y; Johnson DW; Vesey DA; Hawley CM; Clarke M; Topley N;
    Perit Dial Int; 2015; 35(2):159-71. PubMed ID: 24711637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Icodextrin Solution on the Preservation of Residual Renal Function in Peritoneal Dialysis Patients: A Randomized Controlled Study.
    Chang TI; Ryu DR; Yoo TH; Kim HJ; Kang EW; Kim H; Chang JH; Kim DK; Moon SJ; Yoon SY; Han SH;
    Medicine (Baltimore); 2016 Mar; 95(13):e2991. PubMed ID: 27043667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biocompatible peritoneal dialysis solution preserves residual renal function.
    Kim S; Oh KH; Oh J; Kim SJ; Chung W; Song YR; Na KY; Oh YK; Ahn C; Kim SG; Tan KC
    Am J Nephrol; 2012; 36(4):305-16. PubMed ID: 23007025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biocompatible dialysis fluids for peritoneal dialysis.
    Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
    Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.
    Johnson DW; Clarke M; Wilson V; Woods F; Brown FG
    BMC Nephrol; 2010 Sep; 11():25. PubMed ID: 20843375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.
    Haag-Weber M; Krämer R; Haake R; Islam MS; Prischl F; Haug U; Nabut JL; Deppisch R;
    Nephrol Dial Transplant; 2010 Jul; 25(7):2288-96. PubMed ID: 20197284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Routine Bioimpedance-Guided Fluid Management Provide Additional Benefit to Non-Anuric Peritoneal Dialysis Patients? Results from COMPASS Clinical Trial.
    Oh KH; Baek SH; Joo KW; Kim DK; Kim YS; Kim S; Oh YK; Han BG; Chang JH; Chung W; Na KY;
    Perit Dial Int; 2018; 38(2):131-138. PubMed ID: 29386302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.
    Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi MG; Tan SH; Voss D;
    Nephrol Dial Transplant; 2012 Dec; 27(12):4445-53. PubMed ID: 22859794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.